Development of acute myocarditis as a complication of COVID-19
Article Sidebar
Main Article Content
Abstract
The definite proofs of injury of SARS-CoV-2 infection on cardiovascular system are existing. Heart damage may be as primary without lung injury mentioned in literature «the heart phenotype», as secondary which is developed under lung injury and named «mixed cardio-pulmonary phenotype». The reason of prevalence of one or another phenotype is unknown but with confidence it can be confirmed that myocardial injury worsens the patient’s prognosis. The clinical case concernes the 19-year-old patient after new coronavirus infection COVID-19. The ilness courced in mild form, without lung injury. Myocarditis is clinically fixed after 2 weeks after coronavirus symptoms beginning. In our case repeated сonsistent hypertermia observed since 17 day of disease, the level of C-reactive proteine was elevated. The patient was evaluated after COVID-19. Echocardiography was done, it has been revealed segmentary and global strain decrease. Acute myocarditis was suggested and confirmed by magnetic resonance investigation (MRI) with gadolinium enhancement. Carvedilol 3,125 mg twice daily with dose titration to 25 mg twice, zophinapril 7,5 mg twice a day, spironolacton 25 mg daily, colchicin 0,5 mg twice daily, trimetazidiin 80 mg daily, phisical load restricition, rational nutrition were prescribed to the patient. Repeated MRI demonstrated resolution of acute myocarditis, only elements of light focal unischemic myocardial fibrosis were remained. Conclusion is that in patients with COVID-19 can develop myocarditis. The mechanism of development of this complication is unknown and needs further investigation.
Article Details
Keywords:
References
Протокол надання медичної допомоги для лікування коронавірусної хвороби (COVID-19). Затверджено Наказом Міністерства охорони здоров’я України 02 квітня 2020 р. № 762 (у редакції наказу Міністерства охорони здоров’я України від 20 вересня 2021р. №1979). URL: https://moz.gov.ua/uploads/6/33091-dn_1979_20_09_2021_dod.pdf.
Al-Zakhari R, Upadhya G, Galligan S, Shehaj F. The Myth of Colchicine in Treating Myopericarditis: Case Report and Literature Review. Cureus. 2020;12(6):e8933. doi:https://doi.org/10.7759/cureus.8933.
Biesbroek PS, Beek AM, Germans T, et al. Diagnosis of myocarditis: Current state and future perspectives. Int J Cardiol. 2015;191:211-9. doi: https://doi.org/10.1016/j.ijcard.2015.05.008.
Caforio AL, Pankuweit S, Arbustini E, et al.; European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34(33):2636-48, 2648a-2648d. doi: https://doi.org/10.1093/eurheartj/eht210.
Cocco G, Chu DC, Pandolfi S. Colchicine in clinical medicine. A guide for internists. Eur J Intern Med. 2010;21(6):503-8. doi: https://doi.org/10.1016/j.ejim.2010.09.010.
Deftereos S, Giannopoulos G, Papoutsidakis N, et al. Colchicine and the heart: pushing the envelope. J Am Coll Cardiol. 2013;62(20):1817-25. doi: https://doi.org/10.1016/j.jacc.2013.08.726.
Driggin E, Madhavan MV, Bikdeli B. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol. 2020;75(18):2352–2371. doi: https://doi.org/10.1016/j.jacc.2020.03.031.
Esfandiarei M, McManus BM. Molecular biology and pathogenesis of viral myocarditis. Annu Rev Pathol. 2008;3:127-155. doi: https://doi.org/10.1146/annurev.pathmechdis.3.121806.151534.
Ferreira VM, Schulz-Menger J, Holmvang G, et al. Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations. J Am Coll Cardiol. 2018;72(24):3158-76. doi:https://doi.org/10.1016/j.jacc.2018.09.072.
Finkelstein Y, Aks SE, Hutson JR, et al. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol. 2010;48:407-14. doi: https://doi.org/10.3109/15563650.2010.495348.
Fried JA, Ramasubbu K, Bhatt R, et al. The Variety of Cardiovascular Presentations of COVID-19. Circulation. 2020;141(23):1930-36. doi: https://doi.org/10.1161/CIRCULATIONAHA.120.047164.
Gultekin N, Kucukates E. Microtubule inhibition therapy by colchicine in severe myocarditis especially caused by Epstein–Barr and cytomegalovirus co-infection during a two-year period: a novel therapeutic approach. J Pak Med Assoc. 2014;64(12):1420-3.
Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin. Eur Heart J. 2021;42(2):206. doi: https://doi.org/10.1093/eurheartj/ehaa190.
Imazio M, Brucato A, Cemin R, et al; ICAP Investigators. A randomized trial of colchicine for acute pericarditis. N Engl J Med. 2013;369(16):1522-8. doi: https://doi.org/10.1056/NEJMoa1208536.
Inciardi RM, Lupi L, Zaccone G. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):819-24. doi:https://doi.org/10.1001/jamacardio.2020.1096.
Kim I-C, Kim JY, Kim HA, Han S. COVID-19-related myocarditis in a 21-year-old female patient. Eur Heart J. 2020;41(19):1859. doi: https://doi.org/10.1093/eurheartj/ehaa288.
Kociol RD, Cooper LT, Fang JC. Recognition and initial management of fulminant myocarditis: a scientific statement from the American Heart Association. Circulation. 2020;141(6):e69–e92. doi: https://doi.org/10.1161/CIR.0000000000000745.
Leung YY, Yao Hui LL, Kraus VB. Colchicine-Update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015;45(3):341-50. doi: https://doi.org/10.1016/j.semarthrit.2015.06.013.
McDonagh TA, Metra M, Adamo M, et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. https://doi.org/doi:10.1093/eurheartj/ehab368.
Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20(6):355-62. doi: https://doi.org/10.1038/s41577-020-0331-4.
Papadopoulos C, Patoulias D, Teperikidis E, et al. Colchicine as a potential therapeutic agent against cardiovascular complications of COVID-19: an exploratory review. SN Compr Clin Med. 2020;2(9):1419-29. doi: https://doi.org/10.1007/s42399-020-00421-x.
Punja M, Mark DG, McCoy JV, et al. Electrocardiographic manifestations of cardiac infectious-inflammatory disorders. Am J Emerg Med. 2010;28(3):364-77. doi: https://doi.org/10.1016/j.ajem.2008.12.017.
Rabbani AB, Parikh RV, Rafique AM. Colchicine for the Treatment of Myocardial Injury in Patients With Coronavirus Disease 2019 (COVID-19) – An Old Drug With New Life? JAMA Netw Open. 2020;3(6):e2013556. doi: https://doi.org/10.1001/jamanetworkopen.2020.13556.
Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846-8. doi: https://doi.org/10.1007/s00134-020-05991-x.
Sala S, Peretto G, Gramegna M, et al. Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection. Eur Heart J. 2020;41(19):1861-2. doi: https://doi.org/10.1093/eurheartj/ehaa286.
Schlesinger N, Firestein BL, Brunetti L. Colchicine in COVID-19: an Old Drug, New Use. Curr Pharmacol Rep. 2020;6(4):137-45. doi: https://doi.org/10.1007/s40495-020-00225-6.
Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802-10. doi: https://doi.org/10.1001/jamacardio.2020.0950.
Tardif J-C, Kouz S, Waters DD, et al Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381:2497–505. doi: https://doi.org/10.1056/NEJMoa1912388.
Tavazzi G, Pellegrini C, Maurelli M, et al. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail. 2020;22(5):911-5. doi: https://doi.org/10.1002/ejhf.1828.
Wang WK, Wang B, Cao XH, Liu YS. Spironolactone alleviates myocardial fibrosis via inhibition of Ets-1 in mice with experimental autoimmune myocarditis. Exp Ther Med. 2022;23(6):369. doi: https://doi.org/10.3892/etm.2022.11296.
Zeng JH, Liu YX, Yuan J, et al. First case of COVID-19 complicated with fulminant myocarditis: a case report and insights. Infection. 2020;48(5):773-7. doi: https://doi.org/10.1007/s15010-020-01424-5.
Zhyvotovska A, Yusupov D, Foronjy R, et al. Insights into Potential Mechanisms of Injury and Treatment Targets in COVID-19, SARS-Cov-2 Infection. Int J Clin Res Trials. 2020;5(1):147. doi: https://doi.org/10.15344/2456-8007/2020/147.